158 related articles for article (PubMed ID: 11906550)
1. Neoadjuvant chemotherapy or primary surgery in advanced epithelial ovarian carcinoma.
Kayikçioglu F; Köse MF; Boran N; Calişkan E; Tulunay G
Int J Gynecol Cancer; 2001; 11(6):466-70. PubMed ID: 11906550
[TBL] [Abstract][Full Text] [Related]
2. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer.
Zhao D; Wu LY; Wang XB; Li XG
Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
4. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
[TBL] [Abstract][Full Text] [Related]
5. The Impact of Percent Reduction in CA-125 Levels on Prediction of the Extent of Interval Cytoreduction and Outcome in Patients With Advanced-Stage Cancer of Müllerian Origin Treated With Neoadjuvant Chemotherapy.
Mahdi H; Maurer KA; Nutter B; Rose PG
Int J Gynecol Cancer; 2015 Jun; 25(5):823-9. PubMed ID: 25828750
[TBL] [Abstract][Full Text] [Related]
6. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery.
Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E
Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962
[TBL] [Abstract][Full Text] [Related]
7. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
[TBL] [Abstract][Full Text] [Related]
8. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
9. Survival of patients with advanced ovarian cancer treated with intermittent chemotherapy following cytoreductive surgery and adjuvant chemotherapy.
Amikura T; Aoki Y; Kase H; Watanabe M; Sato T; Fujita K; Kurata H; Tanaka K
Int J Clin Oncol; 2002 Feb; 7(1):45-50. PubMed ID: 11942049
[TBL] [Abstract][Full Text] [Related]
10. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer.
da Costa AA; Valadares CV; Baiocchi G; Mantoan H; Saito A; Sanches S; Guimarães AP; Achatz MI
Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S971-8. PubMed ID: 26014155
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and clinical outcome of patients with recurrent early-stage epithelial ovarian cancer: an Italian multicenter retrospective study.
Gadducci A; Cosio S; Zola P; Sostegni B; Fuso L; Sartori E
Int J Gynecol Cancer; 2013 Mar; 23(3):461-8. PubMed ID: 23370604
[TBL] [Abstract][Full Text] [Related]
13. Treatment Outcomes of Epithelial Ovarian Cancers Following Maximum Cytoreduction and Adjuvant Paclitaxel-Carboplatin Chemotherapy: Egyptian NCI Experience.
Nassar HR; Zeeneldin AA; Helal AM; Ismail YM; Elsayed AM; Elbassuiony MA; Moneer MM
Asian Pac J Cancer Prev; 2015; 16(16):7237-42. PubMed ID: 26514517
[TBL] [Abstract][Full Text] [Related]
14. Primary debulking surgery versus neo-adjuvant chemotherapy in stage III/IV ovarian cancer: Comparison of perioperative morbidity and survival data in Pakistani women.
Chishti U; Aziz AB
J Pak Med Assoc; 2015 Mar; 65(3):306-9. PubMed ID: 25933567
[TBL] [Abstract][Full Text] [Related]
15. Impact of neoadjuvant chemotherapy cycles prior to interval surgery in patients with advanced epithelial ovarian cancer.
Colombo PE; Labaki M; Fabbro M; Bertrand M; Mourregot A; Gutowski M; Saint-Aubert B; Quenet F; Rouanet P; Mollevi C
Gynecol Oncol; 2014 Nov; 135(2):223-30. PubMed ID: 25220627
[TBL] [Abstract][Full Text] [Related]
16. The role of diaphragmatic surgery during interval debulking after neoadjuvant chemotherapy: an analysis of 74 patients with advanced epithelial ovarian cancer.
Tsolakidis D; Amant F; Van Gorp T; Leunen K; Neven P; Vergote I
Int J Gynecol Cancer; 2010 May; 20(4):542-51. PubMed ID: 20686373
[TBL] [Abstract][Full Text] [Related]
17. A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy.
May T; Comeau R; Sun P; Kotsopoulos J; Narod SA; Rosen B; Ghatage P
Int J Gynecol Cancer; 2017 May; 27(4):668-674. PubMed ID: 28441250
[TBL] [Abstract][Full Text] [Related]
18. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy alone for patients 75 years and older with epithelial ovarian cancer-is interval cytoreductive surgery still needed?
Klein DA; Mann AK; Freeman AH; Liao CI; Kapp DS; Chan JK
Am J Obstet Gynecol; 2020 Feb; 222(2):170.e1-170.e11. PubMed ID: 31421122
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography/computed tomography predictors of overall survival in stage IIIC/IV ovarian cancer.
Risum S; Loft A; Engelholm SA; Høgdall E; Berthelsen AK; Nedergaard L; Lundvall L; Høgdall C
Int J Gynecol Cancer; 2012 Sep; 22(7):1163-9. PubMed ID: 22810969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]